(Reuters) – The U.S. drugs regulator said on Wednesday it had authorized AstraZeneca’s antibody cocktail to prevent COVID-19 infections in individuals who have weak immune systems or a history of severe side effects from coronavirus vaccines.
While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, AstraZeneca’s therapy Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.
“Vaccines have proven to be the best defense available against COVID-19,” said Patrizia Cavazzoni, director of the Food and Drug Administration’s Center for Drug Evaluation and Research.
Pre-exposure prevention with Evusheld is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended, the FDA said.
(Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)
